Budd-Chiari Syndrome Caused by Polycythemia Vera: A Case Report

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2023 Oct 23

PMID 37868390

Authors

Joana Camoes Neves

Filipa Rodrigues

Isabel Apolinario

Marina Alves

Olinda Sousa Caetano

Affiliations

Soon will be listed here.

Abstract

Budd-Chiari syndrome (BCS) is a rare condition characterized by the obstruction of hepatic venous outflow. It has various potential etiologies, with myeloproliferative neoplasms representing the most prevalent pathogenic association. Here, we present the case of a 51-year-old male who manifested abdominal pain and ascites. Subsequent clinical investigation revealed the presence of BCS secondary to a myeloproliferative syndrome, specifically polycythemia vera. This case emphasizes the importance of diagnosing BCS and conducting a thorough investigation into its underlying etiology.

References

Smalberg J, Arends L, Valla D, Kiladjian J, Janssen H, Leebeek F . Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood. 2012; 120(25):4921-8. DOI: 10.1182/blood-2011-09-376517. View

Simonetto D, Yang H, Yin M, de Assuncao T, Kwon J, Hilscher M . Chronic passive venous congestion drives hepatic fibrogenesis via sinusoidal thrombosis and mechanical forces. Hepatology. 2014; 61(2):648-59. PMC: 4303520. DOI: 10.1002/hep.27387. View

Bastos Metzger P, Costa K, Silva S, Dos Santos V, Nunes V, Freire M . Budd-Chiari syndrome due to hepatic venous web outflow obstruction: percutaneous treatment with balloon angioplasty. J Vasc Bras. 2021; 20:e20200133. PMC: 8336983. DOI: 10.1590/1677-5449.200133. View

Murad S, Plessier A, Hernandez-Guerra M, Fabris F, Eapen C, Bahr M . Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med. 2009; 151(3):167-75. DOI: 10.7326/0003-4819-151-3-200908040-00004. View

Brancatelli G, Vilgrain V, Federle M, Hakime A, Lagalla R, Iannaccone R . Budd-Chiari syndrome: spectrum of imaging findings. AJR Am J Roentgenol. 2007; 188(2):W168-76. DOI: 10.2214/AJR.05.0168. View

Garcia-Pagan J, Valla D . Primary Budd-Chiari Syndrome. N Engl J Med. 2023; 388(14):1307-1316. DOI: 10.1056/NEJMra2207738. View

Ollivier-Hourmand I, Allaire M, Goutte N, Morello R, Chagneau-Derrode C, Goria O . The epidemiology of Budd-Chiari syndrome in France. Dig Liver Dis. 2018; 50(9):931-937. DOI: 10.1016/j.dld.2018.04.004. View

Westbrook R, Lea N, Mohamedali A, Smith A, Orr D, Roberts L . Prevalence and clinical outcomes of the 46/1 haplotype, Janus kinase 2 mutations, and ten-eleven translocation 2 mutations in Budd-Chiari syndrome and their impact on thrombotic complications post liver transplantation. Liver Transpl. 2012; 18(7):819-27. DOI: 10.1002/lt.23443. View

Valla D, Casadevall N, Lacombe C, Varet B, GOLDWASSER E, Franco D . Primary myeloproliferative disorder and hepatic vein thrombosis. A prospective study of erythroid colony formation in vitro in 20 patients with Budd-Chiari syndrome. Ann Intern Med. 1985; 103(3):329-34. DOI: 10.7326/0003-4819-103-3-329. View

10.

Mancuso A . An update on management of Budd-Chiari syndrome. Ann Hepatol. 2014; 13(3):323-6. View

11.

Gaman M, Cozma M, Manan M, Srichawla B, Dhali A, Ali S . Budd-Chiari syndrome in myeloproliferative neoplasms: A review of literature. World J Clin Oncol. 2023; 14(3):99-116. PMC: 10052333. DOI: 10.5306/wjco.v14.i3.99. View

12.

Murphy P, Thomas J, McClelland T . Pain Management of Budd Chiari Syndrome in the Primary Care Setting: A Case Study. Innov Pharm. 2021; 12(2). PMC: 8326689. DOI: 10.24926/iip.v12i2.3906. View

13.

Mukhiya G, Zhou X, Han X, Jiao D, Pokhrel G, Li Y . Evaluation of outcome from endovascular therapy for Budd-Chiari syndrome: a systematic review and meta-analysis. Sci Rep. 2022; 12(1):16166. PMC: 9519873. DOI: 10.1038/s41598-022-20399-x. View

14.

Hamulyak E, Daams J, Leebeek F, Biemond B, Te Boekhorst P, Middeldorp S . A systematic review of antithrombotic treatment of venous thromboembolism in patients with myeloproliferative neoplasms. Blood Adv. 2021; 5(1):113-121. PMC: 7805324. DOI: 10.1182/bloodadvances.2020003628. View

15.

Goulding C, Uttenthal B, Foroni L, Duke V, Traore A, Kottaridis P . The JAK2(V617F) tyrosine kinase mutation identifies clinically latent myeloproliferative disorders in patients presenting with hepatic or portal vein thrombosis. Int J Lab Hematol. 2008; 30(5):415-9. DOI: 10.1111/j.1751-553X.2007.00973.x. View